Savita Rangarajan

Publications

90 publications

Page 4 of 9

Targeting of antithrombin in hemophilia A or B with RNAi therapy

K. John Pasi, Savita Rangarajan, Pencho Georgiev, Tim Mant, Michael D. Creagh, Toshko Lissitchkov, David Bevan, Steve Austin, Charles R. Hay, Inga Hegemann, Rashid Kazmi, Pratima Chowdary, Liana Gercheva-kyuchukova, Vasily Mamonov, Margarita Timofeeva, Chang-heok Soh, Pushkal Garg, Akshay Vaishnaw, Akin Akinc, Benny Sørensen & Margaret V. Ragni, 2017, New England Journal of Medicine, 377(9), 819-828

DOI: 10.1056/NEJMoa1616569

Type: article

The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors

Steven R. Lentz, Savita Rangarajan, Faraizah A. Karim, Philip D. Andersen, Per Arkhammar, Gabriela Rosu & Johnny Mahlangu, 2017, Blood Coagulation & Fibrinolysis, 28(3), 224-229

DOI: 10.1097/MBC.0000000000000584

Type: article

Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A

Paul Batty, Steve K. Austin, Kate Khair, Carolyn M. Millar, Ben Palmer, Savita Rangarajan, Jan-Phillip Stümpel, Murugaiyan Thanigaikumar, Thynn T. Yee & Daniel P. Hart, 2017, British Journal of Haematology, 176(5), 796-804

DOI: 10.1111/bjh.14543

Type: article

Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study

Kathelijn Fischer, Roshni Kulkarni, Beatrice Nolan, Johnny Mahlangu, Savita Rangarajan, Giulia Gambino, Lei Diao, Alejandra Ramirez-santiago, Glenn F Pierce & Geoffrey Allen, 2017, The Lancet Haematology, 4(2), e75-e82

DOI: 10.1016/S2352-3026(16)30193-4

Type: article

Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study

V. Jiménez-Yuste, J. Oldenburg, S. Rangarajan, R. Peiró-Jordán & E. Santagostino, 2016, Haemophilia, 22(6), 859-865

DOI: 10.1111/hae.12986

Type: article

Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial

M. Carcao, M. Zak, F. Abdul Karim, H. Hanabusa, S. Kearney, M.-y. Lu, P. Persson, S. Rangarajan & E. Santagostino, 2016, Journal of Thrombosis and Haemostasis, 14(8), 1521-1529

DOI: 10.1111/jth.13360

Type: article

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

P. Collins, E. Chalmers, P. Chowdary, D. Keeling, M. Mathias, J. O'donnell, K. J. Pasi, S. Rangarajan & A. Thomas, 2016, Haemophilia, 22(4), 487-498

DOI: 10.1111/hae.13013

Type: article

Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety

T. Lissitchkov, K. Hampton, M. Von Depka, C. Hay, S. Rangarajan, E. Tuddenham, K. Holstein, A. Huth-kühne, I. Pabinger, S. Knaub, J. Bichler & J. Oldenburg, 2016, Haemophilia, 22(2), 225-231

DOI: 10.1111/hae.12793

Type: article

Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors

V. Jiménez-Yuste, J. Oldenburg, S. Rangarajan, M. H Kurth, J. Bozzo & E. Santagostino, 2016, Haemophilia, 22(1), e71-e74

DOI: 10.1111/hae.12857

Type: article

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

B. Nolan, J. Mahlangu, D. Perry, G. Young, R. Liesner, B. Konkle, S. Rangarajan, S. Brown, H. Hanabusa, K. J. Pasi, I. Pabinger, S. Jackson, L. M. Cristiano, X. Li, G. F. Pierce & G. Allen, 2016, Haemophilia, 22(1), 72-80

DOI: 10.1111/hae.12766

Type: article

Professor Savita Rangarajan

Connect with Savita

Publications